Profile data is unavailable for this security.
Mergers & acquisitions
Acquired company | LLY:NYQ since announced | Transaction value |
---|---|---|
Mablink Bioscience SAS | 42.46% | -- |
POINT Biopharma Global Inc | 63.19% | 1.38bn |
Versanis Bio Inc | 102.08% | 1.93bn |
Emergence Therapeutics AG | 91.51% | 8.33m |
Sigilon Therapeutics Inc | 91.51% | 316.64m |
Data delayed at least 15 minutes, as of Jun 15 2024 00:00 BST.